natgillin/translations-raw huggingface dataset:
Table 5 Chemotherapy regimen used in combination with imatinib in study I2301 
Preglednica 5 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom v študiji I2301
• Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. 
• odraslih in pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi;
FIP1L1-PDGFRα-positive in other 3 published reports. 
FIP1L1-PDGFRα pozitivni so bili še štirje bolniki s HES, ki so jih opisovali v drugih 3 objavljenih poročilih.
C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza Spain 
C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza Španija
Major cytogenetic response, haematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints. 
Pomemben citogenetični odziv, hematološki odziv, molekularni odziv (ovrednotenje minimalne rezidualne bolezni), čas do pospešene faze ali blastne krize in preživetje so poglavitni sekundarni cilji opazovanja.
20 out of the 50 (40%) patients in cohort 5 received haematopoietic stem cell transplant. 
od 50 bolnikom (40 %) v 5. kohorti so presadili krvotvorne matične celice.
The length of the capsule is from 19.1 mm to 19.7 mm and the width is 6.91 mm. Imatinib Teva 400 mg hard capsules 
Dolžina kapsule znaša od 19,1 mm do 19,7 mm in je široka 6,91 mm. Imatinib Teva 400 mg trde kapsule
• The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. 
• zdravljenje odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
In the event of overdose the patient should be observed and appropriate symptomatic treatment given. 
V primeru prevelikega odmerjanja je treba bolnika opazovati in mu nuditi ustrezno simptomatsko zdravljenje.
A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%) 
Pomemben odziv združuje tako popolne kot delne odzive: popoln (0 % Ph+ metafaz), delen (1
(1 h), days 26, 46; 
(1 ura), 26., 46. dan;
For the patients treated at 600 mg, the current estimates for median progression-free-survival and overall survival were 22.9 and 42.5 months, respectively. 
Za bolnike, zdravljene s 600 mg, je trenutna ocena medianega preživetja brez napredovanja bolezni in preživetja nasploh 22,9 oziroma 42,5 meseca.
The effect of imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen. 
Vpliv zdravljenja z imatinibom na preživetje v kronični fazi pri novo diagnosticirani KML so nadalje preiskovali z retrospektivno analizo zgoraj opisanih podatkov o imatinibu skupaj s prvotnimi podatki druge študije faze III, v kateri so uporabljali IFN+Ara-C s povsem enakim režimom zdravljenja (n = 325).
If you forget to take Imatinib Teva - If you forget a dose, take it as soon as you remember. 
Če ste pozabili vzeti zdravilo Imatinib Teva - Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
When needed, discontinuation of Imatinib Teva treatment may be considered. 
Če je treba, velja razmisliti o prekinitvi zdravljenja z zdravilom Imatinib Teva.
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v. 
Ara-C: citozin arabinozid; CP: ciklofosfamid; DEX: deksametazon; MTX: metotreksat; 6-MP: 6merkaptopurin; VM26: tenipozid; VCR: vinkristin; IDA: idarubicin; i.v.
In this retrospective analysis, the superiority of imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) imatinib patients and 63 (19.4%) IFN+Ara-C patients had died. 
V tej retrospektivni analizi se je z vidika celotnega preživetja imatinib izkazalo za boljše od IFN+Ara-C (p < 0,001): v 42 mesecih je umrlo 47 (8,5 %) bolnikov z imatinibom in 63 (19,4 %) bolnikov z IFN+Ara-C.
Accelerated phase 
Predhodna faza
When and how to take Imatinib Teva - Take Imatinib Teva with a meal. 
Kdaj in kako jemati zdravilo Imatinib Teva Zdravilo Imatinib Teva vzemite z obrokom hrane.
Complete (Confirmed3) [95% CI] 
popoln (potrjen3) [95 %-ni interval zaupanja] delen
For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs. 
Za odrasle bolnike z relapsom ali neodzivno Ph+ ALL je imatinib kot monoterapija v odmerku 600 mg/dan varen in učinkovit ter ga lahko prejemajo dokler ne pride do napredovanja bolezni.
Major molecular response criteria: in the peripheral blood reduction of ≥ 3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline. 
Kriteriji pomembnega molekularnega odziva: zmanjšanje količine Bcr-Abl transkriptov v periferni krvi za ≥ 3 logaritme (merjeno s kvantitativno PCR določitvijo reverzne transkriptaze v realnem času) glede na standardizirane izhodiščne vrednosti.
Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients. 
Pri tem je pomembno, da je 27,7 % bolnikov doseglo tudi pomemben citogenetični odziv, ki je bil pri 20,4 %
One large, open-label, multicentre, international randomised phase III study has been conducted in patients with newly diagnosed Ph+ CML. 
Eno veliko odprto, multicentrično, mednarodno randomizirano študijo tretje faze so opravili pri bolnikih z na novo diagnosticirano Ph+ KML.
- Women who might become pregnant are advised to use effective contraception during treatment. 
Ženskam, ki bi lahko zanosile, med zdravljenjem priporočamo uporabo učinkovite kontracepcijske metode.
For patients with reduction in Bcr-Abl transcripts of at least 3 logarithms at 12 months, the probability of remaining free from progression to accelerated phase/blast crisis was 99% at 84 months. 
Pri bolnikih z zmanjšanjem števila transkriptov Bcr-Abl za vsaj 3 logaritme pri 12 mesecih je bila verjetnost, da bolezen ne napreduje v pospešeno fazo/blastno krizo, po 84 mesecih 99 %.
Of these 11 patients, 4 patients escalated up to 800 mg daily, 2 of whom regained a cytogenetic response (1 partial and 1 complete, the latter also achieving a molecular response), while of the 7 patients who did not escalate the dose, only one regained a complete cytogenetic response. 
Od teh 11 bolnikov so 4 bolnikom zvečali odmerek na 800 mg na dan, od njih sta 2 spet dobila citogenetični odziv (1 delnega in 1 popolnega, le-ta je dosegel tudi molekularni odziv), medtem ko je od 7 bolnikov, pri katerih odmerka niso zvečali, le eden spet dobil popolni citogenetični odziv.
Imatinib Teva inhibits the growth of these cells. 
Zdravilo Imatinib Teva zavira rast teh celic.
The median duration of therapy in the published literature ranged between 4 weeks and more than 20 months. 
Mediano trajanje zdravljenja v objavljeni literaturi se je gibalo od 4 tednov do več kot
Check whether cytopenia is related to leukaemia (marrow aspirate or biopsy). 
1.Preverite, ali je citopenija povezana z levkemijo (aspirat ali biopsija kostnega mozga).
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed. 
primeru, da je koncentracija protiteles proti ADAMTS13 zvišana, aktivnost ADAMTS13 pa nizka, se zdravljenja z zdravilom Imatinib Teva ne sme nadaljevati.
However, since the effects of low-dose exposure of the infant to imatinib are unknown, women taking imatinib should not breastfeed. 
Vendar učinki izpostavljenosti dojenčka majhnim odmerkom imatiniba niso znani, zato ženske, ki jemljejo imatinib ne smejo dojiti.
days 1-3; 
1.-3. dan;
Not applicable Not applicable 
se smiselno ne uporablja se smiselno ne uporablja
Lymphoid blast crisis 
Limfoidna blastna kriza
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). 
Izkušnje z uporabo imatiniba pri bolnikih z MDS/MPD v povezavi s preureditvijo genov za PDGFR so zelo omejene (glejte poglavje 5.1).
The active substance imatinib demonstrates an environmental risk for sediment organisms. 
Zdravilna učinkovina imatinib predstavlja okoljsko tveganje za organizme v sedimentih.
Imatinib inhibits signalling and proliferation of cells driven by dysregulated PDGFR and Abl kinase activity. 
Imatinib zavira signaliziranje in proliferacijo celic, ki ju povzroča napačno uravnavano delovanje PDGFR in aktivnosti Abl kinaze.
Remission induction 
Indukcija remisije
Haematological response1 Complete haematological response (CHR) No evidence of leukaemia (NEL) 
Hematološki odziv1 popolni hematološki odziv (CHR) nobenih znakov levkemije (NEL)
The first 77 patients were started at 400 mg, the protocol was subsequently amended to allow higher dosing and the remaining 158 patients were started at 600 mg. 
Prvih 77 bolnikov je začelo zdravljenje z odmerkom 400 mg, pozneje je bil protokol dopolnjen, da je omogočil večje odmerjanje in je preostalih 158 bolnikov začelo s 600 mg.
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys. 
Hepatotoksičnost Presnova imatiniba poteka predvsem v jetrih in le 13 % se izloča skozi ledvice.
• Eye pain or deterioration in vision, bleeding in the eyes. 
• bolečine v očeh ali poslabšanje vida, očesna krvavitev,
• Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. 
• odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) in/ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFRα.
Imatinib Teva may do the same to some other medicines. 
Zdravilo Imatinib Teva lahko enako vpliva na nekatera druga zdravila.
Do not stop taking Imatinib Teva unless your doctor tells you to. 
Ne prenehajte jemati zdravila Imatinib Teva, razen če vam tako naroči zdravnik.
A total of 71 (12.8%) and 85 (15.4%) patients died in the imatinib and IFN+Ara-C groups, respectively. 
Skupno je umrlo 71 (12,8 %) bolnikov iz skupine z imatinibom in 85 (15,4 %) iz skupine z IFN+AraC.
Therapy should be initiated by a physician experienced in the treatment of patients with haematological malignancies and malignant sarcomas, as appropriate. 
4.2 Odmerjanje in način uporabe Zdravljenje mora začeti zdravnik, izkušen v zdravljenju bolnikov s hematološkimi malignimi boleznimi in malignimi sarkomi, kot je primerno.
Other medicines and Imatinib Teva 
Druga zdravila in zdravilo Imatinib Teva
In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2 times the average paediatric exposure at the highest recommended dose of 340 mg/m2. 
V študiji toksičnih učinkov na razvoj mladičev so opažali vpliv na rast ter zakasnjeno odpiranje nožnice in ločevanje prepucija pri izpostavljenosti, ki ustreza približno 0,3 do 2-kratniku izpostavljenosti, do kakršne v povprečju pride pri otrocih, ki prejemajo največji priporočeni odmerek 340 mg/m2.
Imatinib Teva is a medicine containing an active substance called imatinib. 
Zdravilo Imatinib Teva je zdravilo, ki vsebuje zdravilno učinkovino z imenom imatinib.
Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23% (90%CI [1.16-1.30]). 
Imatinib je v odmerku 400 mg dvakrat na dan zaviral presnovo metoprolola s CYP2D6, tako da sta se Cmax in AUC metoprolola povečali za približno 23 % (90 % IZ [1,16-1,30]).
Depression, libido decreased, anxiety 
depresija, zmanjšan libido, anksioznost redki:
The more frequent adverse reactions included gastrointestinal haemorrhages, conjunctivitis and elevation of transaminases or bilirubin. 
Med pogostejšimi neželenimi reakcijami so bili gastrointestinalne krvavitve, konjunktivitis in zvišanje aminotransferaz ali bilirubina.
These patients received imatinib for a median of 47 months (range 24 days - 60 months). 
Ti bolniki so prejemali imatinib mediano 47 mesecev (od 24 dni do 60 mesecev).
In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients. 
Kaže, da je pri bolnikih z okvarjenim delovanjem ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih z normalnim delovanjem ledvic, verjetno zato, ker je pri teh bolnikih zvišana vrednost alfa kislega glikoproteina (AGP - alpha-acid glycoprotein) v plazmi, proteina, ki veže imatinib.
These are blood diseases in which some blood cells (named eosinophils) start growing out of control. 
To so bolezni krvi, pri katerih se začnejo nenadzorovano razraščati nekatere krvne celice (imenovane eozinofilci).
Imatinib Teva can help you to fight this condition. 
Zdravilo Imatinib Teva vam lahko pomaga pri premagovanju te bolezni.
Posology for Ph+ ALL in paediatric patients Dosing for children should be on the basis of body surface area (mg/m2). 
Odmerjanje pri Ph+ ALL pri pediatričnih bolnikih Odmerjanje za otroke mora temeljiti na telesni površini (mg/m2).
If a severe non-haematological adverse reaction develops with imatinib use, treatment must be withheld until the event has resolved. 
Če med uporabo imatiniba nastopi huda nehematološka neželena reakcija, je treba Zdravljenje prekiniti, dokler reakcija ne izzveni.
In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with DFSP. 
Pri odraslih in pediatričnih bolnikih temelji učinkovitost imatiniba na celotni hematološki in citogenetični odzivnosti in preživetju brez napredovanja bolezni pri KML, na hematološki in citogenetični odzivnosti pri Ph+ ALL, MDS/MPD, na hematološki odzivnosti pri HES/CEL ter na objektivni odzivnosti odraslih bolnikov z DFSP.
Treatment schedule: On the basis of the existing data, imatinib has been shown to be effective and safe when administered at 600 mg/day in combination with chemotherapy in the induction phase, the consolidation and maintenance phases of chemotherapy (see section 5.1) for adult patients with newly diagnosed Ph+ ALL. 
Razpored zdravljenja: Na osnovi obstoječih podatkov se je imatinib izkazal kot učinkovit in varen, če je bil pri odraslih bolnikih z novo diagnosticirano Ph+ALL uporabljen v odmerku 600 mg/dan v kombinaciji s kemoterapijo v začetni fazi, konsolidacijski in vzdrževalni fazi kemoterapije (glejte poglavje 5.1).
Imatinib Teva may cause your body to retain water (severe fluid retention). 
Zaradi zdravila Imatinib Teva lahko telo zadržuje vodo (lahko pride do hudega zastajanja tekočine).
The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations. 
Način uporabe Predpisani odmerek mora bolnik vzeti peroralno z obrokom in velikim kozarcem vode, da se čim bolj zmanjša tveganje draženja prebavil.
When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. 
dni pred parjenjem in nato ves čas do 6. dne brejosti, ni bilo nikakršnega učinka na parjenje ali na število brejih samic.
Study ADE04 Prephase 
Študija ADE04
How long to take Imatinib Teva Keep taking Imatinib Teva every day for as long as your doctor tells you. 
Koliko časa jemati zdravilo Imatinib Teva Zdravilo Imatinib Teva jemljite vsak dan, dokler vam zdravnik ne naroči, da ga prenehate jemati.
If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 260 mg/m2. 
Če citopenija ni povezana z levkemijo, zmanjšajte odmerek imatiniba na 260 mg/m2.
Imatinib in combination with chemotherapy induction (see Table 4) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients). 
Imatinib je v kombinaciji z indukcijo s kemoterapijo (glejte preglednico 3) povzročil popolni hematološki odziv pri 93 % (147 od 158 za oceno primernih bolnikov) in pomembni citogenetični odziv pri 90 % (19 od 21 za oceno primernih bolnikov).
Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v. 
Konsolidacijsko zdravljenje izmenična kemoterapija: visokoodmerna kemoterapija z MTX 1 g/m i.v.
Maximal plasma concentrations of imatinib in patients are 2-4 µmol/l, consequently an inhibition of CYP2D6 and/or CYP3A4/5-mediated metabolism of co-administered drugs is possible. 
Največje koncentracije imatiniba v plazmi bolnikov so 2-4 μmol/l, zato je možna inhibicija sočasno uporabljanih zdravil s presnovo, ki poteka preko CYP2D6 in/ali CYP3A4/5.
With 7 years follow-up, there were 93 (16.8%) progression events in the imatinib arm: 37 (6.7%) involving progression to accelerated phase/blast crisis, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC, and 10 (1.8%) CML unrelated deaths. 
Po 7 letih spremljanja je bilo v kraku z imatinibom 93 (16,8 %) dogodkov, ki pomenijo napredovanje bolezni: 37 (6,7 %) jih je vključevalo napredovanje v pospešeno fazo/blastno krizo, 31 (5,6 %) izgubo pomembnega citogenetičnega odziva, 15 (2,7 %) izgubo popolnega hematološkega odziva ali zvišanje WBC, 10 (1,8 %) pa je bilo smrti brez povezave s KML.
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p<0.001; OS p<0.0001) in two studies (AJP01 and AUS01). 
V dveh študijah (AJP01 in AUS01) sta preživetje brez bolezni (DSFdisease-free survival) in celokupno preživetje (OS - overall survival) konstantno presegala 1 leto in sta bila daljša kot pri zgodovinskih kontrolah (DFS p<0,001; OS p<0,0001).
2 Headache was the most common in GIST patients. 
Glavobol je bil najpogostejši pri bolnikih z GIST.
Patients showing lack of response (lack of complete haematological response (CHR) at 6 months, increasing WBC, no major cytogenetic response (MCyR) at 24 months), loss of response (loss of CHR or MCyR) or severe intolerance to treatment were allowed to cross over to the alternative treatment arm. 
Bolnikom, pri katerih se je pokazala odsotnost odziva (odsotnost popolnega hematološkega odziva (CHR - complete haematological response) pri 6 mesecih, povečanje WBC, odsotnost pomembnega citogenetičnega odziva (MCyR - major cytogenetic response) pri 24 mesecih), izguba odziva (izguba CHR ali MCyR) ali težko neprenašanje zdravljenja, je bilo dovoljeno preiti na krak alternativnega zdravljenja.
At 84 months the estimated overall survival is 86.4% (83, 90) vs. 83.3% (80, 87) in the randomised imatinib and the IFN+Ara-C groups, respectively (p=0.073, log-rank test). 
Po 84 mesecih je ocenjeno celotno preživetje v skupini randomizirani na imatinib 86,4 % (83, 90) v primerjavi s 83,3 % (80, 87) v skupini randomizirani na IFN+Ara-C (p= 0,073, test log-rank).
Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8 weeks of therapy. 
Zdravljenje z imatinibom povzroči hiter odziv pri na novo diagnosticiranih pediatričnih bolnikih s popolnim hematološkim odzivom 78 % po 8 tednih zdravljenja.
What you need to know before you take Imatinib Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Imatinib Teva
Muscle spasm and cramps, musculoskeletal pain including myalgia9, arthralgia, bone pain10 
mišični spazmi in krči, mišično-skeletne bolečine, vključno z mialgijo9, artralgijo in bolečinami v kosteh10
- Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL). 
- s hipereozinofilnim sindromom (HES) in/ali kronično eozinofilno levkemijo (CEL).
Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)* 
ileus/zapora črevesja*, gastrointestinalna perforacija*, divertikulitis*, žilne ektazije antruma želodca (GAVE)*
The tablet is debossed with “IT” and “1” at each side of the score line. 
Tableta ima oznako “IT” na eni in “1” na drugi strani zareze.
This will help protect you from stomach problems when taking Imatinib Teva. 
Tako boste laže preprečili težave z želodcem, do katerih pride pri jemanju zdravila Imatinib Teva.
BCR-ABL tyrosine kinase inhibitors (TKIs) have been associated with thrombotic microangiopathy (TMA), including individual case reports for Imatinib Teva (see section 4.8). 
Zaviralce tirozin kinaze BCR-ABL povezujejo z razvojem trombotične mikroangiopatije, o posameznih primerih so poročali tudi pri uporabi zdravila Imatinib Teva (glejte poglavje 4.8).
The tablet is debossed with “IT” and “4” at each side of the score line. 
Tableta ima oznako “IT” na eni in “4” na drugi strani zareze.
18 Gy in 10 fractions for patients that are CNS3 at diagnosis VCR (1.5 mg/m2/day, IV): days 1, 29 
18 Gy v 10 frakcijah za bolnike, ki imajo ob postavitvi diagnoze CNS3 VCR (1,5 mg/m2/dan, i.v.
Considering the combined concentration of imatinib and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose). 
Pri seštevku koncentracij imatiniba in njegovega presnovka, je pri največji zaužiti količini materinega mleka na dan, mogoče pričakoviti nizko skupno izpostavljenost dojenčka zdravilu in presnovku (~10 % terapevtskega odmerka).
The rate of haematological response was 70% with a duration of 2-3 months. 
70 %, njegovo trajanje pa 2-3 mesece.
For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of still water or apple juice. 
Bolnikom, ki ne morejo pogoltniti filmsko obloženih tablet, lahko tablete dispergiramo v kozarcu navadne vode ali jabolčnega soka.
Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8 months in the imatinib and IFN arms, respectively. 
Sedem let po vključitvi zadnjega bolnika je bilo mediano trajanje zdravljenja z zdravili prvega izbora v kraku z imatinibom 82 mesecev, v kraku z IFN pa 8 mesecev.
Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with imatinib. 
Bolnikom je treba razložiti, da lahko med zdravljenjem z imatinibom doživijo neželene učinke, na primer vrtoglavost, meglen vid ali somnolenca.
- If you are a woman who is pregnant or might get pregnant and are trying to open the capsules, you should handle the contents with caution in order to avoid skin-eye contact or inhalation. 
Če ste noseči ali bi lahko zanosili, ravnajte pri odpiranju kapsule z vsebino pazljivo in se izogibajte stiku zdravila z očmi preko rok ali vdihavanju zdravila.
The estimated rate of progression-free survival at 84 months was 81.2% in the imatinib arm and 60.6% in the control arm (p<0.001). 
Ocenjeni delež preživelih brez napredovanja bolezni pri 84 mesecih je bil 81,2 % na kraku z imatinibom in 60,6 % na kontrolnem kraku (p < 0,001).
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and ALL patients. 
Spojina selektivno zavira proliferacijo in inducira apoptozo pri Bcr-Abl pozitivnih celičnih linijah, pa tudi pri svežih limfatičnih celicah bolnikov s KML, s prisotnim kromosomom